{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:50:41Z","timestamp":1778500241493,"version":"3.51.4"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.cjca.2017.07.007","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T02:15:27Z","timestamp":1500516927000},"page":"1254-1265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["New Developments in Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"33","author":[{"given":"Robert M.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E.","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Liebregts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandan S.","family":"Anavekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Veselka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2017.07.007_bib1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib2","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A\u00a0novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O\u2019Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.07.007_bib3","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/eurheartj\/ehv693","article-title":"Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry","volume":"37","author":"Veselka","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.07.007_bib4","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.jacc.2011.06.073","article-title":"Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy a multicenter north american registry","volume":"58","author":"Nagueh","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/ehjci\/jeu291","article-title":"Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: an expert consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association","volume":"16","author":"Cardim","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.07.007_bib6","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.07.007_bib7","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/hrt.2003.014969","article-title":"Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography","volume":"90","author":"Moon","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.07.007_bib8","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.jacc.2010.05.007","article-title":"Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy","volume":"56","author":"Bruder","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib9","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jacc.2010.05.010","article-title":"Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy","volume":"56","author":"O\u2019Hanlon","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.jacc.2004.03.035","article-title":"The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy","volume":"43","author":"Moon","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib11","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/heartjnl-2015-307682","article-title":"Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis","volume":"101","author":"Briasoulis","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.07.007_bib12","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jcmg.2016.02.031","article-title":"Prognostic value of LGE-CMR in HCM: a meta-analysis","volume":"9","author":"Weng","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.07.007_bib13","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/j.ejrad.2012.12.014","article-title":"T1 mapping for detection of left ventricular myocardial fibrosis in hypertrophic cardiomyopathy: a preliminary study","volume":"82","author":"Lu","year":"2013","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jcmg.2012.08.019","article-title":"Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy","volume":"6","author":"Puntmann","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.07.007_bib15","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1016\/j.celrep.2016.11.040","article-title":"Early-onset hypertrophic cardiomyopathy mutations significantly increase the velocity, force, and actin-activated ATPase activity of human beta-cardiac myosin","volume":"17","author":"Adhikari","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.cjca.2017.07.007_bib16","doi-asserted-by":"crossref","unstructured":"Ho CY, Cirino AL, Lakdawala NK, et\u00a0al. Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers [e-pub ahead of print]. Heart. http:\/\/dx.doi.org\/10.1136\/heartjnl-2016\u2013310015, accessed December 4, 2017.","DOI":"10.1136\/heartjnl-2016-310015"},{"key":"10.1016\/j.cjca.2017.07.007_bib17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/jmri.21366","article-title":"Delayed enhancement in hypertrophic cardiomyopathy: comparison with myocardial tagging MRI","volume":"27","author":"Kim","year":"2008","journal-title":"J\u00a0Magn Reson Imaging"},{"key":"10.1016\/j.cjca.2017.07.007_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jacc.2016.11.051","article-title":"Assessment of myocardial microstructural dynamics by in\u00a0vivo diffusion tensor cardiac magnetic resonance","volume":"69","author":"Nielles-Vallespin","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcmg.2016.12.001","article-title":"Cardiac 3D printing and its future directions","volume":"10","author":"Vukicevic","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2017.07.007_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/CIRCULATIONAHA.115.015842","article-title":"Myocardial 3-dimensional printing for septal myectomy guidance in a patient with obstructive hypertrophic cardiomyopathy","volume":"132","author":"Yang","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib21","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1161\/CIR.0b013e318223e230","article-title":"2011 ACCF\/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Gersh","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0735-1097(03)00941-0","volume":"42","author":"Maron","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib23","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1161\/CIRCEP.114.002553","article-title":"Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"8","author":"Vriesendorp","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.amjcard.2015.05.047","article-title":"Independent assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy","volume":"116","author":"Maron","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2016.04.021","article-title":"Validation of the 2014 European Society of Cardiology Sudden Cardiac Death Risk Prediction Model in Hypertrophic Cardiomyopathy in a reference center in South America","volume":"118","author":"Fernandez","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/europace\/euv079","article-title":"Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator","volume":"18","author":"Ruiz-Salas","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2017.07.007_bib27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1161\/CIRCULATIONAHA.113.007094","article-title":"Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy","volume":"130","author":"Chan","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib28","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2009.11.062","article-title":"Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations","volume":"55","author":"Girolami","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib29","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ejhf.144","article-title":"Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy","volume":"16","author":"Wang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2017.07.007_bib30","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/hc4601.097997","article-title":"Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy","volume":"104","author":"Olivotto","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib31","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1253\/circj.CJ-09-0140","article-title":"Clinical impact of atrial fibrillation in patients with hypertrophic cardiomyopathy. Results from Kochi RYOMA Study","volume":"73","author":"Kubo","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.cjca.2017.07.007_bib32","doi-asserted-by":"crossref","first-page":"e001002","DOI":"10.1161\/JAHA.114.001002","article-title":"Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population","volume":"3","author":"Siontis","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2017.07.007_bib33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.316","article-title":"Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)","volume":"17","author":"Guttmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2017.07.007_bib34","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/heartjnl-2016-309406","article-title":"Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"102","author":"Providencia","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.07.007_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacc.2008.11.069","article-title":"The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy","volume":"54","author":"Maron","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib36","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1161\/01.CIR.98.23.2505","article-title":"Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle","volume":"98","author":"Maron","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib37","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1136\/hrt.2009.174292","article-title":"What causes outflow tract obstruction in hypertrophic cardiomyopathy?","volume":"95","author":"Ommen","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.07.007_bib38","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib39","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0735-1097(02)03004-8","article-title":"Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration","volume":"41","author":"Kofflard","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib40","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/heartjnl-2012-303339","article-title":"Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile","volume":"99","author":"Jensen","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.07.007_bib41","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/eurheartj\/ehm117","article-title":"Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy","volume":"28","author":"McLeod","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.07.007_bib42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2017.07.007_bib43","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.111.076257","article-title":"Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy","volume":"126","author":"Sorajja","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib44","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.athoracsur.2012.08.011","article-title":"Outcome of septal myectomy for obstructive hypertrophic cardiomyopathy in children and young adults","volume":"95","author":"Altarabsheh","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.cjca.2017.07.007_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.tcm.2014.09.004","article-title":"The 20 advances that have defined contemporary hypertrophic cardiomyopathy","volume":"25","author":"Maron","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.cjca.2017.07.007_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/01.CIR.52.1.88","article-title":"Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients","volume":"52","author":"Morrow","year":"1975","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib47","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ncpcardio0965","article-title":"Surgery insight: septal myectomy for obstructive hypertrophic cardiomyopathy\u2013the Mayo Clinic experience","volume":"4","author":"Dearani","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.cjca.2017.07.007_bib48","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.pcad.2012.03.002","article-title":"Diversity of mitral valve abnormalities in obstructive hypertrophic cardiomyopathy","volume":"54","author":"Cavalcante","year":"2012","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2017.07.007_bib49","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.jacc.2016.07.735","article-title":"Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures","volume":"68","author":"Hong","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib50","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacc.2015.07.069","article-title":"Transaortic chordal cutting: mitral valve repair for obstructive hypertrophic cardiomyopathy with mild septal hypertrophy","volume":"66","author":"Ferrazzi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib51","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.pcad.2012.03.001","article-title":"Surgical myectomy for hypertrophic cardiomyopathy in the 21st century, the evolution of the \u201cRPR\u201d repair: resection, plication, and release","volume":"54","author":"Swistel","year":"2012","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2017.07.007_bib52","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000454800","article-title":"The use of MitraClip for symptomatic patients with hypertrophic obstructive cardiomyopathy","volume":"137","author":"Thomas","year":"2017","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2017.07.007_bib53","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4244\/EIJY14M08_13","article-title":"Targeting systolic anterior motion and left ventricular outflow tract obstruction in hypertrophic obstructed cardiomyopathy with a MitraClip","volume":"11","author":"Schafer","year":"2015","journal-title":"EuroIntervention"},{"key":"10.1016\/j.cjca.2017.07.007_bib54","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.hlc.2014.01.007","article-title":"MitraClip implantation as a new treatment strategy against systolic anterior motion-induced outflow tract obstruction in hypertrophic obstructive cardiomyopathy","volume":"23","author":"Schafer","year":"2014","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.cjca.2017.07.007_bib55","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.cjca.2016.01.034","article-title":"A\u00a0novel minimally invasive approach for surgical septal myectomy","volume":"32","author":"Mazine","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib56","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamacardio.2016.0252","article-title":"Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US nationwide inpatient database, 2003-2011","volume":"1","author":"Kim","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0140-6736(95)91267-3","article-title":"Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy","volume":"346","author":"Sigwart","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2017.07.007_bib58","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cjca.2011.09.001","article-title":"Long-term effects of varying alcohol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy: a randomized study with a follow-up up to 11 years","volume":"27","author":"Veselka","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib59","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1093\/eurheartj\/eht495","article-title":"Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population","volume":"35","author":"Veselka","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.07.007_bib60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijcard.2016.02.077","article-title":"Low procedure-related mortality achieved with alcohol septal ablation in European patients","volume":"209","author":"Veselka","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib61","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.cjca.2015.02.010","article-title":"Risk and causes of death in patients after alcohol septal ablation for hypertrophic obstructive cardiomyopathy","volume":"31","author":"Veselka","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib62","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/heartjnl-2016-309699","article-title":"Obstruction after alcohol septal ablation is associated with cardiovascular mortality events","volume":"102","author":"Veselka","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.07.007_bib63","doi-asserted-by":"crossref","first-page":"e2194","DOI":"10.4244\/EIJ-D-15-00159","article-title":"Computed tomography angiography planning identifies the target vessel for optimum infarct location and improves clinical outcome in alcohol septal ablation for hypertrophic obstructive cardiomyopathy","volume":"12","author":"Cooper","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.cjca.2017.07.007_bib64","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jcct.2009.10.004","article-title":"Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy","volume":"4","author":"Okayama","year":"2010","journal-title":"J\u00a0Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.cjca.2017.07.007_bib65","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/j.ijcard.2007.06.132","article-title":"Usefulness of multi-detector row computed tomography for the management of percutaneous transluminal septal myocardial ablation in patient with hypertrophic obstructive cardiomyopathy","volume":"129","author":"Mitsutake","year":"2008","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib66","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jacc.2010.07.055","article-title":"Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months\u2019 follow-up in 19 patients","volume":"57","author":"Lawrenz","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib67","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.jacc.2011.09.020","article-title":"Percutaneous radiofrequency septal reduction for hypertrophic obstructive cardiomyopathy in children","volume":"58","author":"Sreeram","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib68","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ijcard.2016.08.123","article-title":"Endocardial radiofrequency septal ablation - A new option for non-surgical septal reduction in patients with hypertrophic obstructive cardiomyopathy (HOCM)?: A systematic review of clinical studies","volume":"222","author":"Poon","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/europace\/euv302","article-title":"Radiofrequency ablation of the interventricular septum to treat outflow tract gradients in hypertrophic obstructive cardiomyopathy: a novel use of CARTOSound(R) technology to guide ablation","volume":"18","author":"Cooper","year":"2016","journal-title":"Europace"},{"key":"10.1016\/j.cjca.2017.07.007_bib70","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/CIRCULATIONAHA.107.688135","article-title":"Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy","volume":"116","author":"Fifer","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib71","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jacc.2009.04.072","article-title":"The case for myocardial ischemia in hypertrophic cardiomyopathy","volume":"54","author":"Maron","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib72","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jacc.2005.10.050","article-title":"Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy","volume":"47","author":"Olivotto","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib73","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa025050","article-title":"Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy","volume":"349","author":"Cecchi","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.07.007_bib74","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/hupa.2000.16659","article-title":"Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia","volume":"31","author":"Basso","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cjca.2017.07.007_bib75","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1161\/CIRCULATIONAHA.106.657023","article-title":"Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging","volume":"115","author":"Petersen","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib76","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0735-1097(91)90869-B","article-title":"Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography","volume":"17","author":"Camici","year":"1991","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib77","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.jacc.2016.07.751","article-title":"Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance","volume":"68","author":"Raphael","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib78","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0735-1097(86)80181-4","article-title":"Intramural (\u201csmall vessel\u201d) coronary artery disease in hypertrophic cardiomyopathy","volume":"8","author":"Maron","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib79","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.amjcard.2004.05.046","article-title":"Coronary hemodynamics in patients with symptomatic hypertrophic cardiomyopathy","volume":"94","author":"Yang","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib80","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/01.CIR.96.3.834","article-title":"Changes in phasic coronary blood flow velocity profile and relative coronary flow reserve in patients with hypertrophic obstructive cardiomyopathy","volume":"96","author":"Kyriakidis","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib81","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s12350-008-9031-3","article-title":"Effects of exercise on the duration of diastole and on interventricular phase differences in patients with hypertrophic cardiomyopathy: relationship to cardiac output reserve","volume":"16","author":"Plehn","year":"2009","journal-title":"J\u00a0Nucl Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib82","doi-asserted-by":"crossref","first-page":"H129","DOI":"10.1152\/ajpheart.00077.2011","article-title":"Effects of alcohol septal ablation on coronary microvascular function and myocardial energetics in hypertrophic obstructive cardiomyopathy","volume":"301","author":"Timmer","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib83","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/hrt.2008.148239","article-title":"Immediate improvement in coronary flow reserve after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy","volume":"95","author":"Jaber","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2017.07.007_bib84","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.fjc.0000248236.43760.86","article-title":"Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy","volume":"48","author":"de Resende","year":"2006","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2017.07.007_bib85","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12265-009-9132-7","article-title":"Experimental therapies in hypertrophic cardiomyopathy","volume":"2","author":"Marian","year":"2009","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.cjca.2017.07.007_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-8587(14)70241-4","article-title":"Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial","volume":"3","author":"Axelsson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2017.07.007_bib87","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib88","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.07.007_bib89","doi-asserted-by":"crossref","first-page":"e003565","DOI":"10.1161\/CIRCHEARTFAILURE.116.003565","article-title":"Ranolazine prevents phenotype development in a mouse model of hypertrophic cardiomyopathy","volume":"10","author":"Coppini","year":"2017","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2017.07.007_bib90","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.jacc.2016.07.758","article-title":"Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME)","volume":"68","author":"Gentry","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.07.007_bib91","doi-asserted-by":"crossref","first-page":"e002764","DOI":"10.1161\/CIRCHEARTFAILURE.115.002764","article-title":"Novel approach targeting the complex pathophysiology of hypertrophic cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) trial","volume":"9","author":"Olivotto","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2017.07.007_bib92","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A\u00a0small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cjca.2017.07.007_bib93","doi-asserted-by":"crossref","first-page":"e0168407","DOI":"10.1371\/journal.pone.0168407","article-title":"A\u00a0small molecule inhibitor of sarcomere contractility acutely relieves left ventricular outflow tract obstruction in feline hypertrophic cardiomyopathy","volume":"11","author":"Stern","year":"2016","journal-title":"PLoS One"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X17303719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X17303719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T23:30:10Z","timestamp":1535585410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X17303719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0828282X17303719"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2017.07.007","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Developments in Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2017.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}